Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News |  Statins: The World Market, 2009-2024Visiongain is proud to announce the release of the brand new report "Statins: The World Market" The world statins market is changing, with patent expires and maturity of the landmark product Lipitor (atorvastatin).
By: Visiongain Ltd. The world statins market is changing, with patent expires and maturity of the landmark product Lipitor (atorvastatin) Statins: The World Market, 2009-2024 provides a comprehensive analysis of the world statins market, compiled using a wealth of research tools – including interviews with key opinion-leaders, examination of commercial databases, company reports, policy documents, industry news and filings. This original study provides extensive sales forecasting, market shares present and future, informed opinion, as well as detailed analysis of unmet needs, pipeline developments and commercial opportunities for statin drugs. Highlights of Statins: The World Market, 2009-2024 include: • Forecasts to 2024 for the overall world statin market, the generic statin market, the branded statin market and the dyslipidaemia market, including all statin types, the leading statin brands, leading manufacturers, country markets and combination statin drugs • Interviews with key-opinion leaders in the field • Examination of strengths, weakness, opportunities and threats facing major stakeholders in the sector – the market drivers and restraints • Analysis and forecasts for the leading statin markets in the US, Japan and Canada, together with leading European and emerging national markets • Analysis of the R&D pipeline for new statins, as well as other lipid-lowering drug types. With full market forecasts for all the major generic statins, this new visiongain report reveals the significant commercial opportunities in new sectors of the statin market. However, significant opportunities exist for original branded products too. With relatively few single statins currently in development, new product developments in statins will mainly focus on statin combination drugs, visiongain predicts. In addition, strong growth in the statins sector will occur in emerging national markets - most notably in China and India - driving global sales. There are vast and expanding existing and potential patient populations for those drugs worldwide. Importantly, there are opportunities for companies to raise sales by maximising patient compliance and accessing new patient groups. Statins: The World Market, 2009-2024 examines strategies for increasing patient compliance there. The report has detailed interviews with key-opinion leaders in this important field. Full interview transcripts are provided – you will not find this information anywhere else. Why you should buy this report: • To receive a comprehensive analysis of the prospects for statins from 2009-2024, including predicted revenues, growth rates, market shares and other key metrics • To identify key pipeline developments and up-and-coming products, both in the field of statins, and for other lipid-lowering therapies • To discover the drivers, restraints, competition and opportunities influencing the global statins market –for leading brands, generics and statin combination drugs • To receive forecasts for leading statin country markets and major emerging markets for statin drugs, including China and India • To find out where that market sector is heading - both technologically and commercially - from the present onwards. Statins: The World Market, 2009-2024 is essential reading for everybody involved in the statins market, revealing prospects for both existing competitors and potential market entrants from the present onwards. Companies Listed Abbott Actavis Aegerion Almirall Alter [Spain] Amarin American Heart Association American Medical Association [US] Apotex Arena Pharmaceuticals [US] Astellas AstraZeneca Atherotech Bagó [Argentina] Bayer Berkeley HeartLab (part of Celera) BioInvent [Sweden] Bristol-Myers Squibb Celera Center for Cardiovascular Disease in Women at Brigham and Women's Hospital Centro Nacional de Investigaciones Cardiovasculares (National Centre for Cardiovascular Research, CNIC) [Spain] Chiesi Choongwae [South Korea] CINFA [Spain] Cobalt Laboratories Cobalt Pharmaceuticals Covidien Daiichi Sankyo Dr. Reddy's Laboratories European Medicines Agency (EMEA) European Society of Cardiology Ferrer Food and Drug Administration (FDA) Galephar Pharmaceutical Research Gedeon Richter Genentech Genfit Genzyme GlaxoSmithKline (GSK) Human Genome Sciences (HGS) Intas Isis Japan Tobacco Johnson & Johnson Kissei Kowa Krka Kyorin LifeCycle Pharma Liposcience Lupin Medicines and Healthcare products Regulatory Agency (MHRA) [UK] Medley [Brazil] Menarini Merck & Co. Merck/Schering- Micro Labs Mitsubishi Tanabe Mochida Mylan Nichi-Iko [Japan] NicOx Nissan Chemical Novartis Par Pfizer Pharmaceutical Product Development (PPD) Pierre Fabre Polpharma Public Citizen [US] Ranbaxy Ratiopharm Recordati Roche Sanofi-Aventis Sawai [Japan] Schering-Plough Sciele [wholly owned subsidiary of Shionogi] Sepracor Servier Shionogi Sigma Pharmaceuticals [Australia] Sigma-Tau SkyePharma Solvay Stada Teva University of Auckland Watson World Health Organization (WHO) Zentiva Zydus Cadila Visiongain ltd. 4th Floor, BSG House, 226-236 City Road, London EC1V 2QY United Kingdom Telephone: +44 (0) 20 7336 6100 Fax: +44 (0) 20 7549 9930 info@visiongainglobal.com Or Visit: http://www.visiongain.com/ Or http://www.visiongain.com # # # Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
